Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: Results of a four-year, randomized trial comparing finasteride versus placebo

Urology

Volumn 54, Issue 4, 1999, Pages 662-669

  Roehrborn, Claus G ^a   Boyle, Peter ^b   Bergner, Donald ^b   Gray, Todd ^b   Gittelman, Marc ^b   Shown, Thomas ^b   Melman, Arnold ^b   Bracken, R Bruce ^b   White, Ralph DeVere ^b   Taylor, Alice ^b   Wang, Daniel ^b   Waldstreicher, Joanne ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FUNCTIONAL ASSESSMENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; URINE FLOW RATE;

ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; URODYNAMICS;

EID: 0032868620     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00232-0     Document Type: Article

References (20)

1. Girman CJ, Epstein RS, Jacobsen SJ, et al: Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 44: 825-831, 1994.
2. Barry MJ, Fowler FJ, O'Leary MP, et al, and the Measurement Committee of the American Urological Association: The American Urological Association's symptom index for benign prostatic hyperplasia. J Urol 148: 1549-1557, 1992.
3. Barry MJ, Fowler FJ, O'Leary MP, et al, and the Measurement Committee of The American Urological Association: Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 33: AS145-AS155, 1995.
4. Cockett ATK, Aso Y, Denis L, et al: Recommendations of the International Consensus Committee, in Cockett ATK, Khoury S, Aso Y, et al (Eds): The Second International Consultation on Benign Prostatic Hyperplasia (BPH). Channel Islands, Scientific Communications International, 1993, pp 553-564.
5. Roehrborn CG: The placebo effect in the treatment of benign prostatic hyperplasia, in Kirby RS, McConnell JD, Fitzpatrick JM, et al (Eds): Textbook of Benign Prostatic Hyperplasia. Oxford, England, Isis Medical Media, 1996, pp 239-258.
6. Sech SM, Montoya JD, Bernier PA, et al: The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring. Urology 51: 242-250, 1998.
7. Gormley GJ, Stoner E, Bruskewitz RC, et al, for the Finasteride Study Group: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327: 1185-1191, 1992.
8. Andersen JT, Ekman P, Wolf H, et al, for the Scandinavian BPH Study Group: Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 46: 631-637, 1995.
9. Nickel JC, Fradet Y, Boake RC, et al, and the PROS-PECT Study Group: Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). Can Med Assoc J 155: 1251-1259, 1996.
10. Marberger MJ, and the PROWESS Study Group: Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. Urology 51: 677-686, 1998.
11. McConnell JD, Bruskewitz R, Walsh P, et al, and the Finasteride Long-Term Efficacy and Safety Study Group: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338: 557-563, 1998.
12. Boyle P, Gould AL, and Roehrborn CG: Prostate vol urne predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48: 398-405, 1996.
13. Andriole GL, Guess HA, Epstein JI, et al: Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled trial. Urology 52: 195-202, 1998.
14. Roehrborn CG, Oesterling JE, Auerbach S, et al, and the HYCAT Investigator Group: Effectiveness and safety of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia in the HYCAT study. Urology 47: 159-168, 1996.
15. Lepor H, Williford WO, Barry MJ, et al: A randomized placebo controlled clinical trial of the safety and efficacy of therapies in men with clinical benign prostatic hyperplasia. N Engl J Med 335: 533-539, 1996.
16. Barry MJ, Williford WO, Chang YC, et al: BPH-specific health status measures in clinical research: how much change in AUA Symptom Index and the BPH Impact Index is perceptible to patients? J Urol 154: 1770-1774, 1995.
17. Boyle P, Roehrborn C, and Gould L: Baseline serum PSA levels predict degree of symptom improvement following therapy of BPH with finasteride. J Urol 157: 134A, 1997.
18. Roehrborn CG, McConnell JD, Lieber M, et al: Serum prostate specific antigen concentration is a powerful predictor of acute urinary retention and need for prostate related surgery in men with clinical benign prostatic hyperplasia. Urology 53: 473-480, 1999.
19. Roehrborn CG, Boyle P, Gould AL, et al: Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 53: 581-589, 1999.
20. Roehrborn CG, Bonilla J, and Waldstreicher J: Serum prostate-specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol (in press).